Literature DB >> 27010544

Dysfunction of Circulating Polymorphonuclear Leukocytes and Monocytes in Ambulatory Cirrhotics Predicts Patient Outcome.

Konstantina Sargenti1, Åsa Johansson2,3, Sara Bertilsson4, Inger Mattsby-Baltzer5, Daniel Klintman4, Evangelos Kalaitzakis4,6.   

Abstract

BACKGROUND: Cirrhosis represents a state of functional immune paresis with increased infection risk. AIMS: To investigate polymorphonuclear (PMN) leukocyte and monocyte function in ambulatory cirrhotics, and their potential relation with cirrhosis etiology or patient outcome.
METHODS: Consecutive ambulatory cirrhotics without current or recent (<1 month) infection or acute decompensation were prospectively enrolled in 2013 and followed for a median time of 20 months until death, transplant or end of 2014. Oxidative burst and phagocytosis of circulating PMNs and monocytes were investigated at baseline and after in vitro Escherichia coli stimulation. Seventeen healthy blood donors served as controls. Baseline clinical and laboratory data as well as follow-up data on the development of cirrhosis complications, including acute-on-chronic liver failure (ACLF), and bacterial infections were collected.
RESULTS: Sixty patients were included (70 % male, median age 63 years, 52 % with alcoholic cirrhosis). Compared to controls, cirrhotics showed increased resting and stimulated burst as well as reduced phagocytosis of PMNs, and increased stimulated monocyte burst (p < 0.05 for all). Alcoholic etiology was not related to PMN or monocyte dysfunction (p > 0.05 for all). In Cox regression analysis, increased stimulated monocyte and PMN burst were independent predictors of sepsis, severe sepsis and ACLF occurrence. Also, increased stimulated monocyte burst was associated with worse transplant-free survival (p < 0.05 for all).
CONCLUSIONS: Stimulated PMN and monocyte oxidative burst are increased in ambulatory cirrhotics without acute decompensation. In turn, these changes are associated to sepsis and ACLF occurrence.

Entities:  

Keywords:  Bacterial infection; Liver cirrhosis; Monocytes; Outcome; Polymorphonuclear leucocytes

Mesh:

Substances:

Year:  2016        PMID: 27010544     DOI: 10.1007/s10620-016-4132-3

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  24 in total

1.  Prostaglandin E2 and leukotriene B4 synthesis by peripheral leucocytes in alcoholics.

Authors:  W J Maxwell; J J Keating; F P Hogan; N P Kennedy; P W Keeling
Journal:  Gut       Date:  1989-09       Impact factor: 23.059

2.  Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M.

Authors:  Khalid A Tazi; Jean-Jacques Quioc; Véronique Saada; Annie Bezeaud; Didier Lebrec; Richard Moreau
Journal:  J Hepatol       Date:  2006-03-31       Impact factor: 25.083

3.  Evidence of neutrophil functional defect despite inflammation in stable cirrhosis.

Authors:  Giovanni Tritto; Zois Bechlis; Vanessa Stadlbauer; Nathan Davies; Rubén Francés; Naina Shah; Rajeshwar P Mookerjee; Jose Such; Rajiv Jalan
Journal:  J Hepatol       Date:  2011-01-12       Impact factor: 25.083

Review 4.  Neutrophils in development of multiple organ failure in sepsis.

Authors:  K A Brown; S D Brain; J D Pearson; J D Edgeworth; S M Lewis; D F Treacher
Journal:  Lancet       Date:  2006-07-08       Impact factor: 79.321

5.  The augmented neutrophil respiratory burst in response to Escherichia coli is reduced in liver cirrhosis during infection.

Authors:  T Bruns; J Peter; S Hagel; A Herrmann; A Stallmach
Journal:  Clin Exp Immunol       Date:  2011-03-17       Impact factor: 4.330

6.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

7.  Patients with stable uncomplicated cirrhosis have normal neutrophil function.

Authors:  R Kirsch; V E Woodburne; E G Shephard; R E Kirsch
Journal:  J Gastroenterol Hepatol       Date:  2000-11       Impact factor: 4.029

8.  Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis.

Authors:  Vanessa Stadlbauer; Rajeshwar P Mookerjee; Stephen Hodges; Gavin A K Wright; Nathan A Davies; Rajiv Jalan
Journal:  J Hepatol       Date:  2008-03-25       Impact factor: 25.083

9.  Impaired monocyte function in liver cirrhosis.

Authors:  A Hassner; Y Kletter; D Shlag; M Yedvab; M Aronson; S Shibolet
Journal:  Br Med J (Clin Res Ed)       Date:  1981-04-18

10.  Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK.

Authors:  Christine Bernsmeier; Oltin T Pop; Arjuna Singanayagam; Evangelos Triantafyllou; Vishal C Patel; Christopher J Weston; Stuart Curbishley; Fouzia Sadiq; Nikhil Vergis; Wafa Khamri; William Bernal; Georg Auzinger; Michael Heneghan; Yun Ma; Wayel Jassem; Nigel D Heaton; David H Adams; Alberto Quaglia; Mark R Thursz; Julia Wendon; Charalambos G Antoniades
Journal:  Gastroenterology       Date:  2014-12-03       Impact factor: 22.682

View more
  2 in total

Review 1.  Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome.

Authors:  Carolina Castillo-Castro; Alexandro José Martagón-Rosado; Rocio Ortiz-Lopez; Luis Felipe Garrido-Treviño; Melissa Villegas-Albo; Francisco Javier Bosques-Padilla
Journal:  World J Hepatol       Date:  2021-11-27

2.  Systemic MCP-1 Levels Derive Mainly From Injured Liver and Are Associated With Complications in Cirrhosis.

Authors:  Alexander Queck; Hannah Bode; Frank E Uschner; Maximilian J Brol; Christiana Graf; Martin Schulz; Christian Jansen; Michael Praktiknjo; Robert Schierwagen; Sabine Klein; Christian Trautwein; Hermann E Wasmuth; Marie-Luise Berres; Jonel Trebicka; Jennifer Lehmann
Journal:  Front Immunol       Date:  2020-03-11       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.